GleamWall
中文EN

ELVN Enliven Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1672619 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-16.7%
TTM EPS YoY6.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-16.8%
ROA-16.4%
ROIC (approx.)-19.4%
Asset turnover—

Leverage & solvency

Liabilities / assets2.3%
Debt / equity0.00x
Current ratio45.95x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.58x
Accruals ratio-6.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$85.86M$80.78M
SG&A expense$33.80M$23.78M
Operating income-$119.66M-$104.55M
Income tax$0$232,000
Net income-$103.69M-$89.02M
EBITDA-$119.36M-$104.25M
EPS (basic)-1.83-1.89
EPS (diluted)-1.83-1.89
Weighted avg. shares (diluted)56.66M47.07M
Balance sheet
Cash & equivalents$98.90M$124.17M
Short-term investments$363.73M$189.32M
Current assets$474.88M$318.13M
PP&E, net$34,000$458,000
Total assets$476.17M$325.76M
Current liabilities$16.57M$15.91M
Total liabilities$16.57M$15.91M
Shareholders' equity$459.60M$309.85M
Shares outstanding59.44M48.94M
Cash flow statement
Operating cash flow-$70.30M-$73.19M
Capital expenditure$158,000$44,000
Free cash flow-$70.46M-$73.24M
Investing cash flow-$173.84M-$36.00M
Financing cash flow$218.87M$133.16M
Depreciation & amortization$300,000$300,000
Stock-based compensation$34.02M$20.17M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.